Skip to main content

Advertisement

Table 2 Univariate analysis of survival after recurrence

From: Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy

Variable   Median SAR (months) p-value
Age < 65 years 36.7 (26.0–47.3) 0.71
  ≥65 years 45.6 (29.4–61.8)  
Sex Male 37.8 (33.6–42.1) 0.49
  Female 55.4 (0.0–110.8)  
Location Proximal 37.8 (13.9–61.8) 0.82
  Distal 38.7 (27.9–49.4)  
Time to recurrence < 1 year 31.7 (5.9–57.6) 0.16
  ≥1 year 44.4 (31.4–57.4)  
Stage II, high risk 49.7 (N/A) 0.36
  III 37.8 (30.2–45.5)  
T-stage T1–3 38.2 (29.0–47.4) 0.31
  T4 28.1 (0.0–64.8)  
N-stage N0–1 49.7 (26.1–73.3) 0.064
  N2 29.3 (11.4–47.3)  
Histology Non-MAC 44.4 (31.2–54.7) 0.003
  MAC 20.0 (4.9–35.0)  
Curative resection after distant recurrence Not done 23.6 (12.1–35.2) < 0.001
Done Not reached  
MSI MSS/MSI-L 38.2 (28.2–48.2) 0.35
  MSI-H 9.3 (1.7–38.2)  
  1. Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, N/A not available